Number of the records: 1  

Clinical adenoviral gene therapy for prostate cancer

  1. 1.
    SYSNO ASEP0351752
    Document TypeJ - Journal Article
    R&D Document TypeThe record was not marked in the RIV
    Subsidiary JČlánek ve WOS
    TitleClinical adenoviral gene therapy for prostate cancer
    Author(s) Schenk, E. (NL)
    Essand, M. (SE)
    Bangma, Ch. H. (NL)
    Barber, Ch. (GB)
    Behr, J.-P. (FR)
    Briggs, S. (GB)
    Carlisle, R. (GB)
    Cheng, W.-S. (SE)
    Danielsson, A. (SE)
    Dautzenberg, I. J. C. (NL)
    Dzojic, H. (SE)
    Erbacher, P. (FR)
    Fisher, K. (GB)
    Frazier, A. (GB)
    Georgopoulos, L. J. (GB)
    Hoeben, R. (NL)
    Kochanek, S. (DE)
    Koppers-Lalic, D. (NL)
    Kraaij, R. (NL)
    Kreppel, F. (DE)
    Lindholm, L. (SE)
    Magnusson, M. (SE)
    Maitland, N. (GB)
    Neuberg, P. (GB)
    Nilsson, B. (SE)
    Ogris, M. (DE)
    Remy, J.-S. (FR)
    Scaife, M. (GB)
    Schooten, E. (NL)
    Seymour, L. (SE)
    Totterman, T. (SE)
    Uil, T. G. (NL)
    Ulbrich, Karel (UMCH-V) RID
    Veldhoven-Zweistra, J. L. M. (NL)
    de Vrij, J. (NL)
    van Weerden, W. (NL)
    Wagner, E. (DE)
    Willemsen, R. (NL)
    Source TitleHuman Gene Therapy. - : Mary Ann Liebert - ISSN 1043-0342
    Roč. 21, č. 7 (2010), s. 807-813
    Number of pages7 s.
    Languageeng - English
    CountryUS - United States
    Keywordsadenovirus ; gene delivery ; prostate cancer
    Subject RIVCD - Macromolecular Chemistry
    UT WOS000279596700003
    DOI10.1089/hum.2009.206
    AnnotationProstate cancer is at present the most common malignancy in men in the Western world. When localized, this disease can be treated by curative therapy such as surgery and radiotherapy. Unfortunately, for advanced stage of the disease only palliative treatment is available. Therefore, there is a clinical need for new treatment modalities that can, on the one hand, enhance the cure rate of primary therapy for localized prostate cancer and, on the other hand, improve the treatment of metastasized disease. Gene therapy is now being explored in the clinic as a treatment option for the various stages of prostate cancer. Current clinical experiences are based predominantly on trials with adenoviral vectors. As the first of a trilogy of reviews on the state of the art and future prospects of gene therapy in prostate cancer, this review focuses on the clinical experiences and progress of adenovirus-mediated gene therapy for this disease.
    WorkplaceInstitute of Macromolecular Chemistry
    ContactEva Čechová, cechova@imc.cas.cz ; Tel.: 296 809 358
    Year of Publishing2011
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.